To evaluate the relative vaccine effectiveness (rVE) of adjuvanted vs high-dose influenza vaccines in preventing laboratory-confirmed influenza in adults aged 65 years or older during the 2023 to 2024 influenza season.
Key Findings:
Adjuvanted and high-dose vaccines showed comparable effectiveness in preventing laboratory-confirmed influenza, with specific effectiveness rates to be detailed in the full study.
The study utilized a robust health care system with comprehensive electronic medical records for accurate data collection.
Interpretation:
Both adjuvanted and high-dose influenza vaccines are effective in older adults, supporting the ACIP's recommendations for their use and highlighting the need for continued vaccination efforts in this vulnerable population.
Limitations:
The study was conducted within a single health care system, which may limit generalizability.
Patients were not prospectively screened or enrolled, relying on retrospective data, which may introduce biases.
Conclusion:
This study provides evidence that both adjuvanted and high-dose influenza vaccines are effective in older adults, contributing to informed vaccination strategies and public health recommendations.
by Amber Hsiao, Thomas Leong, Bruce Fireman, John Hansen, Ousseny Zerbo, Karen B. Jacobson, Lauren D. Liao, Mendel D. M. Haag, Ian McGovern, Bin Zhang, Juliet Dang, Nicola P. Klein
A large English cohort study found influenza hospitalization more than doubled the short-term risk of new-onset diabetes, with prediabetes and critical care admission among the strongest predictors.
